continu initi buy rate pt
sector life scienc tool omic
messag view best way invest genom medicin near-
term bear argument around instrument cycl popseq fund delay creat
attract entri point vs flat sinc juli compani
believ facilit much genom medicin tomorrow think
investor focu emerg clinic sequenc opportun believ
survey support growth acceler think technolog strong
clinic app creat meaning barrier multibillion-dollar market
includ cancer profil liquid biopsi genet test singl cell genom
use platform read nucleic acid nucleic acid basi
understand biolog system research diagnos diseas choos therapi
monitor therapi facilit write dna today limit
competitor fastest grow busi area believ technolog lead
coupl first mover advantag particularli clinic keep one key
technolog genom medicin next decad
platform compani genom longer one tool
compani platform genom instrument half public esoter dx
lab compani compani use sequenc diagnos
use research believ exposur give investor exposur
faster grow diagnost market includ profil earli detect cancer
potenti applic technolog abund given dynam rang
sequenc number applic sequenc expand rapidli
fastest grow diagnost market
near-term risk like understood enough agre bear
still product cycl compani novaseq order contribut larg revenu number
creat difficult out-year instrument comp magnitud
previou year addit longtim investor understand compani product
cycl dynam experienc addit
believ investor know lumpi around popseq around pend pacbio
acquisit announc nov potenti close reiter
revenu rais ep guidanc yesterday think anoth risk past
competit head start research throughput cost per gigabas everyth
view genom data equat much biolog problem data
requir sampl size approach balanc data qualiti throughput
low cost unlik approach view research look tend
use
deep entrench growth durat greater upsid potenti
believ mani investor appreci research market research favor experi
apples-to-appl comparison previous done sequenc
technolog weak adjac technolog like informat synthet long read
librari prep technolog address flaw clinic compani
go fda use platform say mani compani
industri vest interest see continu succeed
emerg research clinic app biggest emerg area life scienc
tool diagnost liquid biopsi singl cell area play strength
higher throughput higher accuraci mostli short read type applic
kol contact state seen technolog run
type applic proprietari survey suggest sequenc oncolog
page analyst certif import disclosur
page analyst certif import disclosur
invest thesi controversi
rate illumina buy pt
view support
alreadi domin market share posit
grow via growth sequenc market
near-term time issu creat pullback stock
competitor catch
fast see adopt clinic sequenc
stock vs flat sinc
central platform everyth genom
product cycl compani new
grow end market fleet
believ consensu overli focus popseq
instrument placement time ignor emerg first
mover advantag clinic sequenc
consum genom market slow
popseq affect compani
pend pacbio nc acquisit close
singl cell liquid biopsi repres sizabl
opportun multi ten billion base market
largest growth area compani come
year like come clinic sequenc
becom specd clinic sequenc creat
sizeabl barrier competitor view
stock histor long-term outperform
compar market expect high
spend bear fruit extend period time
note price close
page analyst certif import disclosur
background outlook
develop manufactur system analysi
genet data compani global leader base market
share revenu sequenc array base solut
purpos compani serv custom research clinic
appli set found headquart
total debt cash
short-term invest
estim sequenc revenu compound-annual-growth-rate
array compound-annual-growth-rate
servic compound-annual-growth-rate period
yoy compon growth
sequenc revenu analyz
page analyst certif import disclosur
genom platform compani
prepar process known librari prep sequenc work differ type
import nucleic acid dna rna na research effect control chain region
nucleic acid interest research decid level depth would like analyz
genom matter
sequenc much dynam rang there almost unlimit number type genom
analysi done sequenc user sequenc instrument
essenti build whatev type genom analysi platform compani want
entir new end market emerg compani special part rang
note throughout report mani interest emerg compani novel diagnost
includ gh nc buy
foundat medicin built proprietari servic sequenc
tool compani bio-rad nc nc genom
txg nc built import part product portfolio around expand potenti
sequenc built built whether proprietari test proprietari data analyt
proprietari way creat sequence- product sequenc epicent
platform almost genom research diagnost built
page analyst certif import disclosur
growth driver could upsid higher throughput clinic project
liquid biopsy/profil potenti fulli appreci
liquid biopsi multibillion-dollar opportun think go
growth driver technolog advanc
liquid biopsi needle-in-a-haystack challeng requir high
sequenc depth lot consum
believ success show much clinic
sequenc penetr oncolog market
compani valid use liquid biopsi attract
innov space
privat compani grail freenom tempu thrive pgd
etc requir amount sequenc possibl prior
area uptak
concept singl cell highli favor essenti
compani technolog sort cell
sequenc partit cell
singl cell sequenc hit inflect point experi
size expand exponenti view
ipo genom rais
competit advantag throughput demonstr grow
demand high throughput sequenc singl cell view
compani space bio-rad becton dickinson
nc grow singl cell revenu doubl
digit current forecast continu base consensu
research rare diseas nipt popul sequenc
offer strong growth driver though think much potenti
alreadi understood near term
think clinic sequenc may move area diagnost
year ago thought technic
possible/cost effect includ autoimmun diseas
adapt use sequenc tcr bcr
identifi antigen associ theoret diseas
txg revenu project estim consensu number via factset
page analyst certif import disclosur
becom specd first mover advantag
accommod flaw
convers around cost around price per vs cost per
also favor highest
custom check suggest research use illumina
paper accuraci number mostli higher low
like oxford nanopor pacbio
lead throughput
throughput matter view
sequenc inher big data research
research power statist signific
believ gener greatest amount data
research dollar usual prefer method
throughput also cost word gener
base call sell low price per base call
believ meaning advantag
limit short read technolog
scaffold synthet long read help
market de novo genom hla type
compani nc
built technolog around fill blind spot
data compani built softwar help map
view mani industri major incent
keep leader
acceler compani broken invest area vc
invest stage entrench act
focus acceler vc invest
page analyst certif import disclosur
research clinician stuck illumina
data comparison show ilmn lower error rate
compar data use want
compar studi studi run
research china inexpens access bgi
genom co nc sequenc
said continu use dont want
introduc tiniest amount data variabl
research talk say trust data
said competit instrument probabl
give accur data take lot usag
get comfort new data
clinic diagnost creat barrier
product servic go fda
regulatori bodi well specif input note
fda-clear test would requir go back
fda test instrument chang
would essenti specd
addit cost barrier associ new test
go fda
alreadi fda cleared/approv test
mani time econom risk make
sens entrench incumb
innov activ clinic sequenc increas
ilmn market share increas
page analyst certif import disclosur
controversi issu focu view
think
popseq interest research beget
research research excit market longer
research lumpi govern customers/contract
research longer term growth backdrop govern
long-term barrier entri research particularli massiv new
popul sequenc effort lower
agre matter sens speed process
genom medicin countri respect health care system
howev believ inevit
believ continu win global govern
concept precis medicin heavili integr
vocabulari govern
believ order
lumpi expect miss/excess
beat quarter
creat oversuppli novaseq go underutil
studi end
think investor focu timing-rel matter
view precis medicin inevit
think
novaseq cost close million dollar piec
place instrument per year
understand logic new instrument placement
becom harder later product cycl understand
instrument revenu comp becom difficult
larg new product launch typic
spike revenu
larg number custom adopt get
increment adopt becom difficult
product cycl becom well-known
street believ like price stock
estim instrument percent total revenu
word comp becom revenu
vs
hard achiev instrument revenu excess
still instrument cycl stori less
thought street
page analyst certif import disclosur
controversi issu focu view
think
particip consum genom market
array busi run rate
estim believ consum genom repres
less half revenu
record year consum genom market hit
standstil market satur consum interest
us consum genom market repres market
interest long term
although would disappoint see ten million
dollar taken concern
compani gener revenu annual
believ next year longer headwind though
consensu view market weak
consum genom market low barrier entri
optimist consensu project come back
excit area view
consum pay product dont clinic util
long term import area genom would
transform genom area peopl spent
larg market overal
pacbio could risk close
pacbio acquisit announc novemb
deal spread suggest meaning risk
dont believ pacbio import even
strongli believ long-term potenti pacbio
technolog
believ pacbio would financi drain
break-up fee vs cash illumina bs
deal close would detriment
view
page analyst certif import disclosur
compani sequenc product includ high mid low throughput instrument high throughput machin cost front
consum cost lower vice versa
product use basic translat research number scientif applic includ target exom whole genom
sequenc genet variat gene express epigenet metagenom
custom life scienc research academ commerci clinician
investor present placement number dec
also offer array use genotyp cnv analysi gene regul epigenet analysi express analysi cytogenet
analysi offer high densiti genom coverag except data qualiti design acceler target whole genom studi
servic includ sequenc genotyp nipt product support servic done compani clia certifi cap accredit lab
page analyst certif import disclosur
page analyst certif import disclosur
companyinstrumentlist priceestim pull throughnumb placementsapprox price/gbprimari marketcompetit dec clinicalflex vs hiseq xcapit intensivehiseq longer researchveri high throughput per genomenot clinic qualitycapit shiseq longer clinic high throughputversatilitytradeoff speed accuracylarg capit outlaynext dec research clinic count applicationversatil larg dec dec clinicalaccuracycan larg project high per gbiseq dec clinicallow better qc pcrhigh cost per basenot use sequenc hiseq hiseq dec per system life scienc tool omic
custom spoken use bgi instrument note similar
result two technolog
fact lab weve spoken said bgi even use bgi data congruenc sale
given similar technolog view bgi base china repres biggest competitor
particularli geographi less patent enforc mani patent expir
origin solexa technolog found believ mani patent could expir
believ bgi compet best price given similar technolog
said still major advantag view
even bgi tri compet lower margin believ would first
word throughput advantag allow also price advantag
given high degre trust research weve spoken seem qualiti control
believ bgi need product definit better consid budget
lofti challeng view
note even china technolog repres larg portion market like
despit fact chines govern highli encourag domest technolog
page analyst certif import disclosur
consid oxford nanopor biggest long-term competit threat
nanopore-bas sequenc theoret offer longer read higher accuraci lower cost
histor howev nanopor sequenc achiev longer read
cost accuraci remain quit step behind accord kol weve spoken
ont tradit use give instrument away charg consum model
word focus research individu rather product scale
addit ont reli evangel sequenc enthusiast instead go larg product
exampl histor ont target big genom center sequenc
concern ont right howev
ont achiev consensu accuraci run
kol contact note technolog still struggl achiev high accuraci mani
project would head-to-head competit
believ ont still three year away enter product scale clinic
sequenc magnitud disrupt
page analyst certif import disclosur
thermo fisher nc ion torrent strong platform lower throughput market
compet well vs miseq case nextseq hiseq
thermo lead salesforc develop content around ion platform
ion torrent short read lower throughput platform
kol contact note use clinic sequenc
mostli small panel solid tumor
find cancer lab accomplish clinician interchang ion torrent base
project
even found mani lab typic use ion primari sequenc due cost
check suggest thermo good solid tumor known genom hotspot
think remain top howev
research weve spoken still cite homopolym issu though believ thermo
suppli custom way fix issu
dont believ platform meaning enough throughput scalabl
view data much lowest cost import featur
ion torrent platform doesnt throughput scalabl accord custom check
page analyst certif import disclosur
roch fail develop diagnost product acquisit genia geneweav
think roch could take lower risk approach sequenc
check suggest roch diagnost leverag abil clinic compani regulatori
think roch rog-ch nc could move proven research technolog
underutil clinic market
roch big player market diagnost revenu current see roch
competit threat
announc intent acquir pacbio novemb
disagre there major differ long read short read market us
differ market pacbio abl get cost enough bring long read
sequenc tradit market
said even deal doesnt close dont think pacbio compet well
circumst base cost
said pacbio almost never compet pacbio focus de novo whole genom
larg bacteri plant anim transcriptom epigenom sequenc larg
even pacbio new smrt cell chip reduc cost technolog repres move
target pacbio
page analyst certif import disclosur
pt base multipl adj ep estim compani trade multipl
prior two year two year forward adj price-to-earnings basi round due slower near term growth
valuat revenu estim year earn compani trade premium valuat
confid compani abil maintain growth note earn miss signific neg effect
stock price
end market depend given signific market share ilmn futur growth depend larg part growth end
market still rel earli adopt
potenti price sequenc declin multipl compani attempt compet includ price
basi think first abl offer genom recogn risk other may forc
price declin way would unbenefici
increas competit need continu develop new improv product could face addit
competit market particip think strong competit posit note
competitor greater resourc custom base product line experi compani pharmaceut
life scienc clinic genom could also start compet busi line
inabl protect proprietari technolog success reli proprietari technolog hold
proprietari posit uncertain due legal financi question intern due patent law intellectu
chang fda rule regul fda consid chang regul regard laboratori develop
test would increas regulatori requir due growth volum increas test
trade fx concern oper numer intern market includ trade disput
signific possibl fx risk
page analyst certif import disclosur
note estim base factset consensu
note valu oct
go view header footer ms offic insert header footer ms offic enter inform
page analyst certif import disclosur
gener trade signific
premium best comp
view innov high
current trade line
past year
stabl domin market share
sequenc view multipl expans
like come share gain rather
possibl innov new product
grow market
direct compar
sequenc term revenu ebitda
earn street use tech
compani compar
industri perspect stock
page analyst certif import disclosur
page analyst certif import disclosur
buyholdsel buy hold sell ptg ptcurrent life scienc tool omic
note valu million except per share
page analyst certif import disclosur
adj incom revenu gross profit expens non oper incom intang incom expens incom non control net share chg margin life scienc tool omic
page analyst certif import disclosur
ask hematologist oncologist hem-onc percent cancer patient molecular profil perform cancer
penetr expect
believ five year ago answer would well
none survey particip said less cancer sequenc
interest asid interview oncologist design survey told time wont find oncologist
doesnt know sequenc
although penetr high believ growth also come project expand via follow
small panel larger panel
larg panel exom
sequenc tumor sequenc micro environ
go view header footer ms offic insert header footer ms offic enter inform
page analyst certif import disclosur
none oncologist survey said sequenc decreas last year
ask scale sequenc chang none oncologist said sequenc decreas
suggest unlik sequenc cancer simpli pass trend
averag score
doctor survey said sequenc increas dramat
hem-onc said sequenc year last year
go view header footer ms offic insert header footer ms offic enter inform
page analyst certif import disclosur
hem-onc believ sequenc clinic util
hem-onc somewhat disagre clinic outcom improv sequenc
go view header footer ms offic insert header footer ms offic enter inform
page analyst certif import disclosur
hem-onc survey plan increas sequenc come year
oddli higher percent hem-onc think improv clinic util suggest
posit factor might improv sequenc
go view header footer ms offic insert header footer ms offic enter inform
page analyst certif import disclosur
survey hem-onc alreadi sequenc put patient therapi
suggest us mani oncologist use sequenc therapi select
believ could increas drug design label requir sequenc
go view header footer ms offic insert header footer ms offic enter inform
page analyst certif import disclosur
